NASDAQ: AVIRAtea Pharmaceuticals Inc Stock
$5.31+0.13 (+2.51%)
Updated Sep 11, 2026
AVIR Price
$5.31
Fair Value Price
$1.16
Market Cap
$425.89M
52 Week Low
$2.78
52 Week High
$6.45
P/E
-2.55x
P/B
2.09x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$165.29M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
-$152M
Beta
0.98
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AVIR Overview
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AVIR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AVIR
Ranked#229 of 459
Ranked#229 of 459
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.12 | A | |
| $6.85 | A | |
| $41.52 | A |
Be the first to know about important AVIR news, forecast changes, insider trades & much more!
AVIR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AVIR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AVIR ($5.31) is overvalued by 356.14% relative to our estimate of its Fair Value price of $1.16 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AVIR ($5.31) is not significantly undervalued (356.14%) relative to our estimate of its Fair Value price of $1.16 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AVIR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AVIR due diligence checks available for Premium users.
Valuation
AVIR fair value
Fair Value of AVIR stock based on Discounted Cash Flow (DCF)
Price
$5.31
Fair Value
$1.16
Overvalued by
356.14%
AVIR ($5.31) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AVIR ($5.31) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AVIR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AVIR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.55x
Industry
8.81x
Market
40.26x
AVIR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.09x
Industry
5.32x
AVIR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AVIR's financial health
Profit margin
Revenue
$0.0
Net Income
-$32.9M
Profit Margin
0%
AVIR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$232.3M
Liabilities
$28.1M
Debt to equity
0.14
AVIR's short-term assets ($228.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVIR's short-term assets ($228.67M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVIR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AVIR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$37.1M
Investing
$34.3M
Financing
$0.0
AVIR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AVIR vs Biotech Stocks
Atea Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.